NEWPORT BEACH, Calif. - Evolus, Inc. (NASDAQ: NASDAQ:EOLS), known for its portfolio of beauty products, recently announced a milestone for its Evolysse™/Estyme® Lift dermal filler, demonstrating statistical superiority over Restylane-L at three and six months in reducing nasolabial fold severity. The company plans to share detailed data during its earnings call scheduled for Tuesday.
The European Lift study, which concluded as a nine-month, blinded, and randomized trial involving 45 patients, achieved its primary endpoint of non-inferiority at four weeks and went on to show superiority at later stages. Patients in the trial received the company's Estyme® Lift on one side of the face and Restylane-L on the other, with outcomes measured on a validated scale.
Evolus' Chief Medical Officer, Dr. Rui Avelar, highlighted that the Evolysse™/Estyme® product line is the first to utilize the proprietary Cold-HA manufacturing process, which aims to preserve the natural structure of hyaluronic acid (HA). Dr. Michael Kaminer, who injected Evolysse™ Lift in the U.S. trial, noted the product's versatility, rapid post-injection recovery, and the natural look of the results.
The global commercial launch of Evolysse™ in the U.S. and Estyme® in the UK and Europe is on track for 2025, with the Lift filler expected to be the most versatile and highest volume product in the line. The filler has received CE Mark approval in Europe and will be submitted for FDA approval in the summer of 2024.
In 2023, Evolus expanded its market reach through exclusive distribution agreements for the novel dermal filler line, developed by Symatese, which increased the company's addressable market by 78% to approximately $6 billion. The company's flagship product Jeuveau® is globally licensed under the name Nuceiva® and is part of its strategy to evolve the aesthetic neurotoxin market.
This news is based on a press release statement and investors can join the earnings call via webcast on the Evolus Investor Relations page or by phone. A replay will be available both telephonically and on the company's website following the call.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.